SEEL - Jazz Pharma's Mixed Earnings And Other News: The Good Bad And Ugly Of Biopharma
Jazz Pharmaceuticals Provides Mixed Results and Updates
Jazz Pharmaceuticals (JAZZ) reported its fourth-quarter and full-year results and the numbers looked mixed. The company’s GAAP net income for the year stood at $523.4 million, up from $447.1 million it had earned for the previous year. On a per-share basis, the net income stood at $9.09, up from $7.30 in the previous year. However, there was decline in fourth-quarter GAAP net income from $159.5 million the previous year to $74 million this year’s fourth quarter.
Jazz Pharmaceuticals also provided corporate updates about its programs. The